Diagnostic of Iron Deficiency by Means of Non Invasive Measurement of Zink Protoporphyrin IX

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03231865

Acronym

ZnPP

Enrollment

300

Registered

2017-07-27

Start date

2017-07-27

Completion date

2018-05-31

Last updated

2018-06-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Iron-deficiency

Brief summary

ZnPP is being build in the case of a functional iron deficiency. Zinc instead of iron is implemented into protoporphyrin IX. This ZincProtoporphyrin (ZnPP) can be detected non invasively. Non invasive and invasive optical measurement of ZnPP will be compared. Additionally ZnPP measurements will be compared to other iron deficiency parameters for validation by the investigators.

Detailed description

Zinc-protoporphyrin (ZnPP) will be measured by a fluorescence technique. Restricted wave light (407/425 nm) is used to detect ZnPP in the bloodstream non-invasively through the oral mucosa. The spectroscopic measurements are translated into a ZnPP value (mumol/mol heme). The non-invasive measurement of ZnPP is validated and compared to optical measurement of ZnPP in whole blood and high performance liquid chromatography (HPLC) measurement of ZnPP in whole blood. The ZnPP value is compared to other iron-deficiency parameters: Ferritin, Transferrin saturation and soluble Transferrin receptor.

Interventions

DIAGNOSTIC_TESTNon-invasive measurement of ZincProtoporphyrin IX

Within 30 seconds, a measurement is performed on the lip of a patient to determine a ZincProtoporphyrin value

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* Patients seen preoperatively in the Anesthestic clinic * Patients \> 18 years of age * Understood and signed patient consent

Exclusion criteria

* transfusion of blood products 8 weeks prior to screening * Pregnancy * Porphyria

Design outcomes

Primary

Measure	Time frame	Description
Validation of the non-invasive ZincProtoporphyrinIX measurement	Baseline	The value is compared to optical measurement of ZincProtoporphyrin in whole blood; in addition the value is compared to HPLC measurement in whole blood

Secondary

Measure	Time frame	Description
Comparison of the ZincProtoporyphyrinIX value to other iron-deficiency parameters	Baseline	The value is compared to Ferritin, Transferrin saturation and soluble transferrin receptor

Countries

Switzerland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026